WO2005065721A3 - Methodes et compositions pour gene non viral ameliore - Google Patents

Methodes et compositions pour gene non viral ameliore Download PDF

Info

Publication number
WO2005065721A3
WO2005065721A3 PCT/US2004/039899 US2004039899W WO2005065721A3 WO 2005065721 A3 WO2005065721 A3 WO 2005065721A3 US 2004039899 W US2004039899 W US 2004039899W WO 2005065721 A3 WO2005065721 A3 WO 2005065721A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
nucleic acid
acid complex
administration
agent
Prior art date
Application number
PCT/US2004/039899
Other languages
English (en)
Other versions
WO2005065721A2 (fr
Inventor
Rajagopal Ramesh
Gopalan Began
Jack A Roth
Original Assignee
University Of Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Texas filed Critical University Of Texas
Publication of WO2005065721A2 publication Critical patent/WO2005065721A2/fr
Publication of WO2005065721A3 publication Critical patent/WO2005065721A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Abstract

L'invention concerne des méthodes destinées à prévenir ou à réduire l'inflammation suite à l'administration d'un complexe de lipide-acide nucléique chez un sujet consistant à administrer au sujet un agent anti-inflammatoire non stéroïdien, un salicylate, un agent antirhumatismal, une anti-histamine ou un agent immunodépresseur avec le complexe de lipide-acide nucléique. L'invention concerne également des méthodes de criblage d'inhibiteurs de la réponse inflammatoire associée à l'administration d'un complexe de lipide-acide nucléique à un sujet, consistant à produire une substance candidate dont on pense qu'elle prévient ou qu'elle inhibe l'inflammation associée à l'administration d'un complexe de lipide-acide nucléique au sujet. L'invention concerne également des compositions contenant un lipide, un acide nucléique ainsi qu'un agent anti-inflammatoire non stéroïdien, un salicylate, un agent antirhumatismal, une anti-histamine ou un agent immunodépresseur.
PCT/US2004/039899 2003-12-30 2004-11-30 Methodes et compositions pour gene non viral ameliore WO2005065721A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53318003P 2003-12-30 2003-12-30
US60/533.180 2003-12-30

Publications (2)

Publication Number Publication Date
WO2005065721A2 WO2005065721A2 (fr) 2005-07-21
WO2005065721A3 true WO2005065721A3 (fr) 2005-12-01

Family

ID=34703519

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/039899 WO2005065721A2 (fr) 2003-12-30 2004-11-30 Methodes et compositions pour gene non viral ameliore

Country Status (2)

Country Link
US (1) US20050143336A1 (fr)
WO (1) WO2005065721A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2429769C (fr) * 2000-12-07 2016-04-26 Board Of Regents, The University Of Texas System Procedes de traitement mettant en application mda-7 humain
WO2002057283A1 (fr) * 2001-01-19 2002-07-25 Baylor College Of Medecine Methodes et compositions utiles dans le diagnostic et le traitement du cancer du sein
US20040009939A1 (en) * 2002-03-05 2004-01-15 Board Of Regent, The University Of Texas System Methods of enhancing immune induction involving MDA-7
US8034790B2 (en) * 2003-12-01 2011-10-11 Introgen Therapeutics Use of MDA-7 to inhibit pathogenic infectious organisms
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
CA2597329C (fr) * 2005-02-08 2016-10-11 Board Of Regents, The University Of Texas System Compositions et methodes faisant intervenir la proteine mda-7 pour le traitement du cancer
WO2007092944A2 (fr) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions et procedes impliquant une therapie de gene et une modulation de proteasome
DE602007007618D1 (de) * 2006-05-18 2010-08-19 Univ Muenchen L Maximilians Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
WO2008106646A2 (fr) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Procédés et formulations pour une thérapie génique topique
WO2008151289A1 (fr) * 2007-06-05 2008-12-11 President And Fellows Of Harvard College Modulation d'une inflammation des voies respiratoires
CA2723358A1 (fr) * 2008-05-05 2009-11-12 Allison B. Reiss Procede pour ameliorer le profil de risque cardiovasculaire d'inhibiteurs de cox
EP2310020B1 (fr) 2008-07-11 2017-03-15 Board of Regents, The University of Texas System Nouveaux acétates de 2-désoxy monosaccharides à activité anticancéreuse
US9409983B2 (en) 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
JP6190723B2 (ja) 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
WO2012142615A2 (fr) * 2011-04-14 2012-10-18 Board Of Regents, The University Of Texas System Auranofine et analogues d'auranofine utiles pour traiter une maladie proliférative et des troubles prolifératifs
US10040853B2 (en) 2011-09-09 2018-08-07 Fred Hutchinson Cancer Research Center Methods and compositions involving NKG2D inhibitors and cancer
EP2791160B1 (fr) 2011-12-16 2022-03-02 ModernaTX, Inc. Compositions de mrna modifiés
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
JP6545660B2 (ja) 2013-04-05 2019-07-17 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗増殖活性を有する２−デオキシ−単糖類のエステル
WO2015048744A2 (fr) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
CA2926218A1 (fr) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides codant pour un recepteur de lipoproteines de faible densite
EP3964200A1 (fr) 2015-12-10 2022-03-09 ModernaTX, Inc. Compositions et procédés permettant d'administrer des agents thérapeutiques
US11845959B2 (en) 2016-06-16 2023-12-19 The Regents Of The University Of California Identification of factor that promotes human HSC self-renewal
AU2017379901B2 (en) * 2016-12-21 2024-02-15 Arbutus Biopharma Corporation Methods for ameliorating infusion reactions
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
WO2019046809A1 (fr) 2017-08-31 2019-03-07 Modernatx, Inc. Procédés de fabrication de nanoparticules lipidiques
AU2019371161A1 (en) 2018-10-31 2021-06-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Biomarkers and methods of use for radiation-induced lung injury
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100448298B1 (ko) * 1995-09-08 2004-12-03 리서치 디벨럽먼트 파운데이션 유전자발현의증진을위한글루코코르티코이드를포함하는약제학적조성물
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6339069B1 (en) * 1996-10-15 2002-01-15 Elan Pharmaceuticalstechnologies, Inc. Peptide-lipid conjugates, liposomes and lipsomal drug delivery
EP0878936A3 (fr) * 1997-05-12 2001-01-24 Victor Company Of Japan, Limited Système de communication et contrôleur de circuits
US6489305B1 (en) * 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
US20020072503A1 (en) * 2000-03-28 2002-06-13 Jiangchun Xu Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002004511A2 (fr) * 2000-07-10 2002-01-17 Board Of Regents, The University Of Texas System Genes du chromosome 3p21.3 constituant des suppresseurs de tumeurs
JP4881503B2 (ja) * 2000-09-19 2012-02-22 ソニー株式会社 コマンド処理方法および無線通信機器
JP3910072B2 (ja) * 2002-01-30 2007-04-25 東洋アルミニウム株式会社 ペースト組成物およびそれを用いた太陽電池

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GOPALAN BEGAN ET AL: "Nanoparticle based systemic gene therapy for lung cancer: molecular mechanisms and strategies to suppress nanoparticle-mediated inflammatory response.", TECHNOLOGY IN CANCER RESEARCH & TREATMENT. DEC 2004, vol. 3, no. 6, December 2004 (2004-12-01), pages 647 - 657, XP009051133, ISSN: 1533-0346 *
GOPALAN BEGAN ET AL: "The anti-inflammatory drug naproxen protects mice from lipoplex-mediated toxicity.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 44, July 2003 (2003-07-01), & 94TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, DC, USA; JULY 11-14, 2003, pages 923, XP001206989, ISSN: 0197-016X *
ITO ISAO ET AL: "Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo.", CANCER GENE THERAPY. NOV 2004, vol. 11, no. 11, November 2004 (2004-11-01), pages 733 - 739, XP002337566, ISSN: 0929-1903 *
RAMESH R ET AL: "Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector.", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY. MAR 2001, vol. 3, no. 3, March 2001 (2001-03-01), pages 337 - 350, XP002337564, ISSN: 1525-0016 *
RAMESH RAJAGOPAL ET AL: "Local and systemic inhibition of lung tumor growth after nanoparticle-mediated mda-7/IL-24 gene delivery.", DNA AND CELL BIOLOGY. DEC 2004, vol. 23, no. 12, December 2004 (2004-12-01), pages 850 - 857, XP002337565, ISSN: 1044-5498 *
TOUSIGNANT J D ET AL: "Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice.", HUMAN GENE THERAPY. 10 DEC 2000, vol. 11, no. 18, 10 December 2000 (2000-12-10), pages 2493 - 2513, XP002337610, ISSN: 1043-0342 *

Also Published As

Publication number Publication date
WO2005065721A2 (fr) 2005-07-21
US20050143336A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
WO2005065721A3 (fr) Methodes et compositions pour gene non viral ameliore
Muñoz et al. Differential contribution of Nox1, Nox2 and Nox4 to kidney vascular oxidative stress and endothelial dysfunction in obesity
WO2005072713A3 (fr) Inhibiteurs de la cholinesterase pour traiter l'inflammation
WO2001083554A3 (fr) Composes anti-inflammatoires et leurs utilisations
CA2404152A1 (fr) Inhibition de l'activite de l'enzyme cyclooxygenase-2
WO2002044183A3 (fr) Composes et leurs utilisations
WO2005099775A3 (fr) Procedes et compositions destines a predire la reaction a un regime therapeutique d'un sujet souffrant d'une maladie associee a la mort cellulaire
WO2006078287A3 (fr) Inhibiteurs de pde4b
SV2006002293A (es) Formulaciones de derivados de [1,4]diazepina[6,7,1,ij] quinolina ref. wyth0123-503 (am101888)
DE502005007725D1 (de) 5-substituierte chinolin- und isochinolin-derivate; ein verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
HK1057899A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
WO2005052753A3 (fr) Utilisation de concepts pour le ciblage de publicités
ATE535526T1 (de) 2-methyl-2-ä4-(3-methyl-2-oxo-8-chinolin-3-yl-2 3-dihydro-imidazo ä4,5-cü chinolinyl)- phenylüpropionitril als lipidkinase-hemmer
WO2009063062A3 (fr) Récepteur gnns et circuit et système de poursuite d'un signal
WO2006130628A3 (fr) Formulations pharmaceutiques et methodes de traitement utilisant ces formulations
WO2006066950A3 (fr) Aminoalcools tricycliques, procedes de realisation associes et utilisation comme anti-inflammatoires
WO2005084654A3 (fr) Procedes et compositions pour le traitement ou la prevention de troubles psychiatriques avec des inhibiteurs de cox-2 seuls et en combinaison avec des antidepresseurs
WO2006024640A3 (fr) Triazolophtalazines
HK1087702A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
Brand et al. Oxidative DNA damage in kidneys and heart of hypertensive mice is prevented by blocking angiotensin II and aldosterone receptors
ATE464307T1 (de) Mif-hemmer
HN2009000968A (es) Compuestos de pirazol y triazol sustituidos como inhibidores de ksp
WO2006041835A3 (fr) Methodes pour inhiber une mort cellulaire ou une inflammation chez un mammifere
WO2007136638A3 (fr) Inhibiteurs du transporteur de la prostaglandine
WO2005105079A3 (fr) Nouveaux imidazoles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase